Prospective Validation of the OHI Index

Launched by MEIR MEDICAL CENTER · May 21, 2023

Keywords

ClinConnect Summary

**Clinical Trial Summary: Prospective Validation of the OHI Index**

This clinical trial is studying a new way to diagnose and predict outcomes for patients with a serious condition called hemophagocytic lymphohistiocytosis (HLH), particularly when it occurs alongside blood cancers. HLH can be life-threatening, and currently, patients with this condition have a low chance of surviving for five years. The researchers have developed a tool called the Optimized HLH Inflammatory (OHI) index, which helps identify patients who might have a worse prognosis based on specific blood tests. The trial aims to understand how common HLH is in patients with blood cancers and how this new index performs in real-life situations.

To participate in this study, you need to be at least 18 years old and have a blood cancer. However, if you have received certain treatments like chemotherapy in the last month, you won't be eligible. If you join the trial, you will undergo tests to measure your blood levels of specific markers to see if they relate to your condition. This research could lead to better ways to identify and treat HLH, ultimately improving care for patients with blood cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with hematologic malignancies
• • At least 18 years old
• Exclusion Criteria:
• • Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)